Multi-feature weight factor extraction and survival risk assessment of hepatocellular carcinoma based on a clinical missing dataset-independent support vector machine
- PMID: 40636794
- PMCID: PMC12212605
- DOI: 10.1016/j.iliver.2022.07.003
Multi-feature weight factor extraction and survival risk assessment of hepatocellular carcinoma based on a clinical missing dataset-independent support vector machine
Abstract
Background: In clinical datasets, the characteristics of an individual patient vary so much that data loss becomes a normal event, which may be a unignorable dilemma in clinical data analysis. Therefore, the construction of a machine learning model aimed at missing clinical datasets (MCD) is of great clinical importance.
Methods: All included patients were divided into two groups according to outcome within a period of up to 36 months or less. The following characteristics (variables) were collected: age, sex, Child-Pugh status, hepatitis status, cirrhosis status, treatment, tumor size, portal vein tumor thrombus, and alpha fetoprotein (μg/mL), and a missing dataset-independent support vector machine (MDI-SVM) independent of missing data was built for the analysis.
Results: A MCD-independent SVM was developed based on clinical data from 1334 patients with hepatocellular carcinoma (HCC) at a single center, which had an accuracy of 84.43% in the survival analysis in the presence of 5% missing data. Based on the different combinations of features, our model calculated five features (tumor size, age, treatment, hepatitis status, and alpha fetoprotein) that had the greatest impact on survival in patients with HCC and extracted their weighting factors.
Conclusions: A MCD-independent SVM was developed to achieve prognosis prediction for patients with HCC in the absence of first-visit data.
Keywords: HCC; MDI-SVM; Machine learning.
© 2022 The Author(s).
Figures





Similar articles
-
Does the Presence of Missing Data Affect the Performance of the SORG Machine-learning Algorithm for Patients With Spinal Metastasis? Development of an Internet Application Algorithm.Clin Orthop Relat Res. 2024 Jan 1;482(1):143-157. doi: 10.1097/CORR.0000000000002706. Epub 2023 Jun 12. Clin Orthop Relat Res. 2024. PMID: 37306629 Free PMC article.
-
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23. Clin Orthop Relat Res. 2024. PMID: 39051924
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
References
-
- Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–1462. - PubMed
-
- Forner A., Reig M., Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. - PubMed
-
- Sherman M. Surveillance for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2014;28(5):783–793. - PubMed
LinkOut - more resources
Full Text Sources